Injective (INJ) is currently trading at $2.97, reflecting a 1.75% increase over the past 24 hours. The price has fluctuated between a low of $2.90 and a high of $3.02 during this period, indicating moderate volatility within a daily range of 0.12%.

The trading volume stands at approximately $40.45 million, which corresponds to a volume-to-market cap ratio of 13.64%. This suggests a healthy trading activity relative to its market capitalization, indicating investor interest in the asset.

Short-term moving averages show mixed signals: the 8 SMA at $2.97 is slightly down by 0.15%, while the 21 SMA at $2.96 is up by 0.38%. The 55 SMA shows a gain of 0.32%, and the longer-term 144 SMA is significantly higher at $2.88 with a 2.96% increase, suggesting a potential upward trend in the longer term.

The 1-hour RSI is at 53, indicating a neutral market condition, while the 7-day RSI at 55 suggests that INJ is slightly overbought but not excessively so. The 7-day price change of 5.12% shows positive momentum, although the 14-day price change of -0.59% indicates some weakness in the medium-term perspective.

Given the all-time high of $52.62 achieved on March 14, 2024, current price levels reflect a significant discount. Despite recent fluctuations, the positive short-term momentum combined with a stable trading volume and favorable long-term moving averages support a bullish outlook.

In conclusion, the data suggests that Injective (INJ) is currently in a moderate recovery phase with potential for further upside. Therefore, the rating for INJ is a Buy, based on positive price momentum and favorable technical indicators in the context of a recovering market sentiment.